The neuroendocrine and behavioral response to dextroamphetamine in normal individuals.
Dextroamphetamine 30 mg and placebo were administered by mouth in a double-blind randomized cross-over trial to ten subjects. Behavior was assessed and blood samples analyzed for growth hormone (GH), prolactin (PRL), homovanillic acid (HVA), and amphetamine. There was a statistically significant increase in well-being following d-amphetamine as compared to baseline and placebo on both the Amphetamine Interview Rating Scale and the Hopkins Mood Scale. No subject became psychotic. There was a statistically significant increase in GH from baseline to peak following d-amphetamine ingestion. When compared to placebo, the increase in GH was invariable and statistically significant for the 90-min sampling. PRL decreased from baseline following both d-amphetamine and placebo and there was no significant drug-placebo difference. Serum HVA was measured at baseline and 120 min, for eight subjects. Six subjects had an increase in HVA following d-amphetamine but there was no significant drug effect.
D000328:Adult; D000339:Affect / Q000187:drug effects; D000661:Amphetamine / Q000097:blood; D001519:Behavior / Q000187:drug effects*; D010054:Brief Psychiatric Rating Scale; D003913:Dextroamphetamine / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006719:Homovanillic Acid / Q000097:blood*; D006801:Humans; D008297:Male; D010648:Phenylacetates / Q000097:blood*; D011388:Prolactin / Q000097:blood*; D011897:Random Allocation
D010648:Phenylacetates; D011388:Prolactin; D013006:Growth Hormone; D000661:Amphetamine; D003913:Dextroamphetamine; D006719:Homovanillic Acid